上海市肾内科临床质量控制中心专家组 通信作者:梅长林,海军军医大学第二附属医院肾脏病科,上海200003,Email: chlmei1954@126.com 【摘要】慢性肾脏病(chronic kidney disease,CKD)已成为全球性的公共卫生问题。“肾脏病预后质量倡议(Kidney Disease Outcome Quality Initiative,KDOQI)”和“改善全球肾脏病预后组织(Kidney Disease: Improving Global Outcomes,KDIGO)”工作组先后制定了CKD 临床实践指南。为提高我国CKD防治水平,在参考国外指南基础上,结合中国特点,我们组织上海市肾脏病专家制定了《CKD 筛查 诊断及防治指南》,并于2017 年发表。该指南对各级全科医师和肾脏病专科医师均有参考价值,有力推动了对CKD的认识和提高了对CKD的管理水平。近年来CKD 研究又取得了很多重大进展,基于临床证据的积累及各种新药的问世,上海市肾内科临床质量控制中心专家组对2017 年版《CKD 筛查 诊断及防治指南》进行了更新和修订,内容主要包括CKD筛查的对象和方式、进展的评估及防治等方面。 【关键词】 慢性肾脏病; 筛查; 诊断; 治疗; 指南 基金项目:上海市临床重点专科基金(shslczdzk02503) DOI:10.3760/cma.j.cn441217-20210819-00067 本文引用:上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南(2022年版)[J]. 中华肾脏病杂志, 2022, 38(5): 453-464. DOI: 10.3760/cma.j.cn441217-20210819-00067. Expert Group on Kidney Clinical Quality Control Center in Shanghai. Guidelines for early screening, diagnosis, prevention and treatment of chronic kidney disease (2022 Edition) [J]. Chinese Journal of Nephrology, 2022, 38(5): 453-464. DOI: 10.3760/cma.j.cn441217-20210819-00067. 前言 诊断和分期标准 三、CKD 分期 基于估算肾小球滤过率(eGFR),CKD 分为5 期[6],见表3。(Ⅰc) CKD 筛查 CKD 进展评估及防治 利益冲突 专家组所有成员均声明不存在利益冲突 上海市肾内科临床质量控制中心专家组成员(按姓名汉语拼音排序): 陈楠(上海交通大学医学院附属瑞金医院)、邓跃毅(上海中医药大学附属龙华医院)、丁小强(复旦大学附属中山医院)、高翔(海军医大学第二附属医院)、郭志勇(海军医大学第一附属医院)、郝传明(复旦大学附属华山医院)、蒋更如(上海交通大学医学院附属新华医院)、马骏(上海市静安区中心医院)、梅长林(海军军医大学第二附属医院)、倪兆慧(上海交通大学医学院附属仁济医院)、牛建英(复旦大学附属第五人民医院)、彭艾(上海市第十人民医院)、彭文(上海市普陀区中心医院)、汪年松(上海市第六人民医院)、王怡(上海中医药大学附属岳阳中西医结合医院)、邬碧波(上海市静安区闸北中心医院)、徐旭东(上海市闵行区中心医院)、余晨(同济大学附属同济医院)、郁胜强(海军医大学第二附属医院)、袁伟杰(上海市第一人民医院)、张金元(海军特色医学中心)、张景红(海军第九〇五医院) 执笔人:高翔、邬碧波 参考文献 [1] Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study[J]. Lancet Glob Health, 2016, 4(5): e307-e319. DOI: 10.1016/S2214-109X(16)00071-1. [2] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822. DOI: 10.1016/S0140-6736(12)60033-6. [3] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志, 2017, 37(1): 28-34. DOI: 10.19538/j.nk2017010108. [4] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Am J Kidney Dis, 2002, 39(2 Suppl 1): S1-S266. [5] Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)[J]. Kidney Int, 2005, 67(6): 2089-2100. DOI: 10.1111/j.1523-1755.2005.00365.x. [6] KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease[J]. Kidney Int Suppl, 2013, 3(1): 1-150. [7] Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2021, 99(1): 34-47. DOI: 10.1016/j.kint.2020.10.012. [8] Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease[J]. Kidney Int, 2020, 98(4S): S1-S115. DOI: 10.1016/j.kint.2020.06.019. [9] Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease[J]. Kidney Int, 2021, 99(3): 559-569. DOI: 10.1016/j.kint.2020.10.026. [10] Bello AK, Alrukhaimi M, Ashuntantang GE, et al. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action[J]. Kidney Int Suppl (2011), 2017, 7(2): 122-129. DOI: 10.1016/j.kisu.2017.07.007. [11] Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med, 2009, 150(9): 604-612. DOI: 10.7326/0003-4819-150-9-200905050-00006. [12] Zelnick LR, Weiss NS, Kestenbaum BR, et al. Diabetes and CKD in the United States Population, 2009-2014[J]. Clin J Am Soc Nephrol, 2017, 12(12): 1984-1990. DOI: 10.2215/CJN.03700417. [13] Seidu S, Barrat J, Khunti K. Clinical update: The important role of dual kidney function testing (ACR and eGFR) in primary care: identification of risk and management in type 2 diabetes[J]. Prim Care Diabetes, 2020, 14(4): 370-375. DOI: 10.1016/j.pcd.2020.02.006. [14] Shlipak MG, Matsushita K, Ärnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function[J]. N Engl J Med, 2013, 369(10): 932-943. DOI: 10.1056/NEJMoa1214234. [15] Lees JS, Welsh CE, Celis-Morales CA, et al. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease[J]. Nat Med, 2019, 25(11): 1753-1760. DOI: 10.1038/s41591-019-0627-8. [16] Nelson RG, Grams ME, Ballew SH, et al. Development of risk prediction equations for incident chronic kidney disease[J]. JAMA, 2019, 322(21): 2104-2114. DOI: 10.1001/jama.2019.17379. [17] Kramer H, Tuttle KR, Leehey D, et al. Obesity management in adults with CKD[J]. Am J Kidney Dis, 2009, 53(1): 151-165. DOI: 10.1053/j.ajkd.2008.10.003. [18] Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update[J]. Am J Kidney Dis, 2020, 76(3 Suppl 1): S1-S107. DOI: 10.1053/j.ajkd.2020.05.006. [19] Ash S, Campbell KL, Bogard J, et al. Nutrition prescription to achieve positive outcomes in chronic kidney disease: a systematic review[J]. Nutrients, 2014, 6(1): 416-451. DOI: 10.3390/nu6010416. [20] Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials[J]. Am J Clin Nutr, 2008, 88(3): 660-666. DOI: 10.1093/ajcn/88.3.660 [21] 中华医学会肾脏病学分会专家组. 糖尿病肾脏疾病临床诊疗中国指南[J]. 中华肾脏病杂志, 2021, 37(3): 255-304. DOI: 10.3760/cma.j.cn441217-20201125-00041. [22] Mills KT, Chen J, Yang W, et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease[J]. JAMA, 2016, 315(20): 2200-2210. DOI: 10.1001/jama.2016.4447. [23] Meuleman Y, Hoekstra T, Dekker FW, et al. Sodium restriction in patients with CKD: a randomized controlled trial of self-management support[J]. Am J Kidney Dis, 2017, 69(5): 576-586. DOI: 10.1053/j.ajkd.2016.08.042. [24] Flythe JE, Chang TI, Gallagher MP, et al. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2020, 97(5): 861-876. DOI: 10.1016/j.kint.2020.01.046. [25] Carey RM, Whelton PK. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline[J]. Ann Intern Med, 2018, 168(5): 351-358. DOI: 10.7326/M17-3203. [26] Linde C, Bakhai A, Furuland H, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom[J]. J Am Heart Assoc, 2019, 8(22): e012655. DOI: 10.1161/JAHA.119.012655. [27] Hirsch S, Hirsch J, Bhatt U, et al. Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success[J]. Am J Nephrol, 2012, 36(5): 430-437. DOI: 10.1159/000343453. [28] Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future[J]. Hypertension, 2015, 66(4): 731-738. DOI: 10.1161/HYPERTENSIONAHA.115.04889. [29] Fu EL, Evans M, Clase CM, et al. Stopping renin⁃angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study[J]. J Am Soc Nephrol, 2021, 32(2): 424-435. DOI: 10.1681/ASN.2020050682. [30] Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis[J]. N Engl J Med, 2014, 371(19): 1771-1780. DOI: 10.1056/NEJMoa1404231. [31] van den Brand J, Ruggenenti P, Chianca A, et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2017, 28(9): 2729-2737. DOI: 10.1681/ASN.2016091022. [32] Justin J, Fayol A, Bruno RM, et al. International guidelines for hypertension: resemblance, divergence and inconsistencies[J]. J Clin Med, 2022, 11(7): 1975. DOI: 10.3390/jcm11071975. [33] Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines[J]. Hypertension, 2020, 75(6): 1334-1357. DOI: 10.1161/HYPERTENSIONAHA.120.15026. [34] Anderson AH, Yang W, Townsend RR, et al. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study[J]. Ann Intern Med, 2015, 162(4): 258-265. DOI: 10.7326/M14-0488. [35] Steuber TD, Lee J, Holloway A, et al. Nondihydropyridine calcium channel blockers for the treatment of proteinuria: a review of the literature[J]. Ann Pharmacother, 2019, 53(10): 1050-1059. DOI: 10.1177/1060028019843644. [36] Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study[J]. Lancet, 2010, 375(9722): 1255-1266. DOI: 10.1016/S0140-6736(09)61966-8. [37] Huo Y, Li W, Webb R, et al. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study[J]. J Clin Hypertens (Greenwich), 2019, 21(1): 67-76. DOI: 10.1111/jch.13437. [38] 中国医疗保健国际交流促进会高血压分会, 中国医师协会心血管分会, 中国高血压联盟, 等. 沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议[J]. 中华高血压杂志, 2021, 29(2): 108-114. DOI: 10.16439/j.issn.1673-7245.2021.02.003. [39] Volpe M, Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic[J]. Vasc Health Risk Manag, 2012, 8: 371-380. DOI: 10.2147/VHRM.S28359. [40] American Diabetes Association. Standards of medical care in diabetes-2010[J]. Diabetes Care, 2010, 33 Suppl 1: S11-S61. DOI: 10.2337/dc10⁃S011. [41] Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference[J]. Am J Kidney Dis, 2014, 64(4): 510-533. DOI: 10.1053/j.ajkd.2014.08.001. [42] American Diabetes Association. Introduction: Standards of Medical Care in Diabetes-2018[J]. Diabetes Care, 2018, 41 Suppl 1: S1-S2. DOI: 10.2337/dc18-Sint01. [43] 中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏疾病防治临床指南[J]. 中华糖尿病杂志, 2019, 11(1): 15-28. DOI: 10.3760/cma.j.issn.1674-5809.2019.01.004. [44] Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 323-334. DOI: 10.1056/NEJMoa1515920. [45] Wanner C, Heerspink H, Zinman B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial[J]. J Am Soc Nephrol, 2018, 29(11): 2755-2769. DOI: 10.1681/ASN.2018010103. [46] Pollock C, Stefánsson B, Reyner D, et al. Albuminuria⁃lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(6): 429-441. DOI: 10.1016/S2213-8587(19)30086-5. [47] Heerspink H, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15): 1436-1446. DOI: 10.1056/NEJMoa2024816. [48] Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7(10): 776-785. DOI: 10.1016/S2213-8587(19)30249-9. [49] Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient[J]. Kidney Int, 2014, 85(6): 1303-1309. DOI: 10.1038/ki.2014.31. [50] 高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识[J]. 中华内科杂志, 2017, 56(3): 235-248. DOI: 10.3760/cma.j.issn.0578-1426.2017.03.021. [51] Kuwabara M, Bjornstad P, Hisatome I, et al. Elevated serum uric acid level predicts rapid decline in kidney function[J]. Am J Nephrol, 2017, 45(4): 330-337. DOI: 10.1159/000464260. [52] 张庆燕, 刘志红. 高尿酸血症与肾脏损伤[J]. 肾脏病与透析肾移植杂志, 2009, 18(3): 266-271. DOI: 10.3969/j.issn.1006-298X.2009.03.014. [53] Chen D, Ma Y, Wang X, et al. Triptolide-containing formulation in patients with autosomal dominant polycystic kidney disease and proteinuria: an uncontrolled trial[J]. Am J Kidney Dis, 2014, 63(6): 1070-1072. DOI: 10.1053/j.ajkd.2014.01.418. [54] Chen Y, Deng Y, Ni Z, et al. Efficacy and safety of traditional Chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial[J]. Am J Kidney Dis, 2013, 62(6): 1068-1076. DOI: 10.1053/j.ajkd.2013.05.005. [55] Zhang L, Li P, Xing CY, et al. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial[J]. Am J Kidney Dis, 2014, 64(1): 57-65. DOI: 10.1053/j.ajkd.2014.01.431. [56] Zheng Y, Cai GY, He LQ, et al. Efficacy and safety of Niaoduqing particles for delaying moderate-to-severe renal dysfunction: a randomized, double-blind, placebo-controlled, multicenter clinical study[J]. Chin Med J (Engl), 2017, 130(20): 2402-2409. DOI: 10.4103/0366-6999.216407. [57] 《中国围透析期慢性肾脏病管理规范》专家组. 中国围透析期慢性肾脏病管理规范[J]. 中华肾脏病杂志, 2021, 37(8): 690-704. DOI: 10.3760/cma.j.cn441217-20210322-00104. [58] KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease[J]. Kidney Int Suppl, 2012, 2(4): 279-335. [59] Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a 'Kidney Disease: Improving Global Outcomes' (KDIGO) Controversies Conference[J]. Kidney Int, 2016, 89(1): 28-39. DOI: 10.1016/j.kint.2015.10.002. [60] Ratcliffe LE, Thomas W, Glen J, et al. Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale[J]. Am J Kidney Dis, 2016, 67(4): 548-558. DOI: 10.1053/j.ajkd.2015.11.012. [61] 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502. DOI: 10.3760/cma.j.cn112137-20210201-00309. [62] Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022. DOI: 10.1056/NEJMoa1901713. [63] Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010. DOI: 10.1056/NEJMoa1813599. [64] Provenzano R, Szczech L, Leong R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials[J]. Clin J Am Soc Nephrol, 2021, 16(8): 1190-1200. DOI: 10.2215/CJN.16191020. [65] Provenzano R, Fishbane S, Szczech L, et al. Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis[J]. Kidney Int Rep, 2021, 6(3): 613-623. DOI: 10.1016/j.ekir.2020.12.018. [66] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004. [67] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11): 993-1004. DOI: 10.1056/NEJMoa1409077. [68] Bavishi C, Messerli FH, Kadosh B, et al. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials[J]. Eur Heart J, 2015, 36(30): 1967-1973. DOI: 10.1093/eurheartj/ehv142. [69] Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure[J]. JACC Heart Fail, 2018, 6(6): 489-498. DOI: 10.1016/j.jchf.2018.02.004. [70] Chang HY, Feng AN, Fong MC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation[J]. J Cardiol, 2019, 74(4): 372-380. DOI: 10.1016/j.jjcc.2019.03.010. [71] House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2019, 95(6): 1304-1317. DOI: 10.1016/j.kint.2019.02.022. [72] 刘志红, 李贵森. 中国慢性肾脏病矿物质和骨异常诊治指南[M]. 第1版. 北京: 人民卫生出版社, 2019. [73] 国家肾脏疾病临床医学研究中心. 中国慢性肾脏病矿物质和骨异常诊治指南概要[J]. 肾脏病与透析肾移植杂志, 2019, 28(1): 52-57. DOI: 10.3969/j.issn.1006-298X.2019.01.012. [74] Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2020, 97(1): 42-61. DOI: 10.1016/j.kint.2019.09.018. [75] 梅长林, 陈晓农, 郝传明, 等. 慢性肾脏病高钾血症风险评估及管理专家建议(2020 版)[J]. 中华医学杂志, 2020, 100(44): 3489-3493. DOI: 10.3760/cma.j.cn112137-20200918-02669. [76] 中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识[J]. 中华肾脏病杂志, 2020, 36(10): 781-792. DOI: 10.3760/cma.j.cn441217-20200721-00139. [77] 梅长林, 陈晓农, 郝传明, 等. 慢性肾脏病高钾血症风险评估模型的建立[J]. 中华医学杂志, 2020, 100(44): 3498-3503. DOI: 10.3760/cma.j.cn112137-20200904-02561. [78] Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia[J]. N Engl J Med, 2015, 372(3): 222-231. DOI: 10.1056/NEJMoa1411487. [79] Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study[J]. Clin J Am Soc Nephrol, 2019, 14(6): 798-809. DOI: 10.2215/CJN.12651018. [80] Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease[J]. Adv Chronic Kidney Dis, 2006, 13(3): 199-204. DOI: 10.1053/j.ackd.2006.04.004. [81] Gilbertson DT, Unruh M, McBean AM, et al. Influenza vaccine delivery and effectiveness in end-stage renal disease[J]. Kidney Int, 2003, 63(2): 738-743. DOI: 10.1046/j.1523-1755.2003.00787.x. [82] Dinits-Pensy M, Forrest GN, Cross AS, et al. The use of vaccines in adult patients with renal disease[J]. Am J Kidney Dis, 2005, 46(6): 997-1011. DOI: 10.1053/j.ajkd.2005.08.032. [83] DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better[J]. Am J Kidney Dis, 2003, 42(6): 1184-1192. DOI: 10.1053/j.ajkd.2003.08.019. [84] Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism[J]. J Clin Invest, 1976, 57(4): 1079-1082. DOI: 10.1172/JCI108350. [85] Lehotský J, Tothová B, Kovalská M, et al. Role of homocysteine in the ischemic stroke and development of ischemic tolerance[J]. Front Neurosci, 2016, 10: 538. DOI: 10.3389/fnins.2016.00538. [86] Wu CC, Zheng CM, Lin YF, et al. Role of homocysteine in end-stage renal disease[J]. Clin Biochem, 2012, 45(16-17): 1286-1294. DOI: 10.1016/j.clinbiochem.2012.05.031. [87] Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: The Renal Substudy of the China Stroke Primary Prevention Trial[J]. JAMA Intern Med, 2016, 176(10): 1443-1450. DOI: 10.1001/jamainternmed.2016.4687. [88] Jardine MJ, Kang A, Zoungas S, et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis[J]. BMJ, 2012, 344: e3533. DOI: 10.1136/bmj.e3533. [89] Chan CT, Blankestijn PJ, Dember LM, et al. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2019, 96(1): 37-47. DOI: 10.1016/j.kint.2019.01.017. [90] 中国医师协会肾脏病医师分会血液透析充分性协作组. 中国血液透析充分性临床实践指南[J]. 中华医学杂志, 2015, 95(34): 2748-2753. DOI: 10.3760/cma.j.issn.0376-2491.2015.34.004. [91] National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update[J]. Am J Kidney Dis, 2015, 66(5): 884-930. DOI: 10.1053/j.ajkd.2015. 07.015. [92] 中国医师协会肾脏内科医师分会, 中国中西医结合学会肾脏疾病专业委员会, 国家肾病专业医疗质量管理与控制中心. 自动化腹膜透析中国专家共识[J]. 中华医学杂志, 2021, 101(6): 388-399. DOI: 10.3760/cma.j.cn112137-20201210-03326. (收稿日期:2021-08-19) (本文编辑:杨克魁) |
|